

# Preventing Regulatory Actions

**FDA Small Business  
Regulatory Education for Industry (REdI)  
Rockville, MD  
September 28, 2017**

**Tonya Wilbon**

Postmarket and Consumer Branch Chief  
Division of Industry and Consumer Education  
Office of Communication and Education  
Center for Devices and Radiological Health  
U.S. Food and Drug Administration

# Poll


**Are you aware of a firm that was subjected to an  
FDA regulatory action?**

**1) Yes**

**2) No**

**3) I am not sure**

# CDRH Regulatory Actions



- CDRH conducted 1,269 regulatory actions during Fiscal Year 2016.
- 6% decrease in regulatory actions from previous Fiscal Year.

# Learning Objectives

- Provide FDA's regulatory authority
- Review the types and purposes of FDA regulatory actions
- Discuss prevention of FDA regulatory action



# FDA Authority

- Federal Food, Drug, and Cosmetic Act  
(Sections 302 – 304, 501, 502, 518, 801, etc.)
- Title 21 Code of Federal Regulations (21 CFR)  
(Part 7, 11, 800-1299, etc.)

# Types of Regulatory Actions

- Regulatory Meeting
- Untitled Letter
- Warning Letter
- Warning Letter with Detention without Physical Examination
- Warning Letter without Detention



# Types of Regulatory Actions continued

- Product Recall
- Seizures
- Injunctions
- Civil Money Penalties
- Criminal prosecution



# Regulatory Meeting

Informs manufacturer of violations/clarifies violations





# Advisory/Administrative Letters

Letter	Firm type	Issued	Written response required	Notify other federal agencies
<b>Untitled Letter</b>	D/F	Within 6 months	No	No
<b>Warning Letter (WL)</b>	Domestic	Within 4 months	Yes	Yes
<b>WL with Detention without Physical Examination</b>	Foreign	Within 4 months	Yes	Yes (Import Alert)
<b>WL without Detention</b>	Foreign	Within 4 months	Yes	Yes

**D:** Domestic Firm

**F:** Foreign Firm

# Product Recall

- Prompts correction/removal of violative device for:
  - Repair
  - Modification
  - Relabeling
  - Inspection
  - Adjustment
- Reduces risk to health
- Can be voluntary or mandatory
- Classified as Class I, II, or III
- Most common type of regulatory action



# Example: Product Recall

- Herpes Simplex Virus (HSV) 1 & 2 Direct IVD Test
  - Poor lamination
  - Leakage into adjacent wells
  - Yield false positives, false negative, or invalid test results
  - Improper patient treatment
  - May cause serious adverse health consequences
- Firm sent “Customer Correction Notice letter” to customers
- Customers were instructed to:
  - run full discs only
  - discard discs even after partial run

# Seizure

- Method used by FDA to take quick control of violative product
- FDA files a “Complaint for Forfeiture” with the courts
- FDA takes possession of violative devices

## Example: Seizure

- Obstetrical/gynecological surgical devices were seized
  - Labeled as sterile or ethylene oxide processed
  - Sterilization not complete
  - 40,000 units affected
- FDA issued Safety Alert
- FDA was accompanied U.S. Marshal service during seizure



# Injunction



- History of continuous significant violative practices
- Civil process to stop or prevent violation of the law
- Use of current evidence of violation of the law
- FDA files a “Complaint for Injunction” with the courts

# Example: Injunction



- Firm that manufactured electrical devices was enjoined
  - Failure to correct significant violations of the QS regulation
- FDA initially issued Warning Letters in 1998 and 1999
- Ordered shutdown of facility immediately
- Entered into Consent Decree of Permanent Injunction
  - Required to hire an expert
  - Expert report firm's status of compliance to FDA
  - Firm must pay for FDA inspections
- Conduct recall

# Civil Money Penalties

- Knowingly aware of violations
- Risk to public health





# Criminal Prosecution

- Applies to individuals and not firms
- Investigations are conducted by special investigators
- FDA works with the United States Department of Justice



# **Most Frequent Violations Cited to Support Regulatory Action**

- I. Processes not validated
- II. Purchasing controls not implemented
- III. CAPA subsystem not implemented

# I. Validate Required Processes

- Identify and validate all processes as required
- Meet and document all predefined acceptance criteria
- Calibrate equipment used
- Document and date all required reviews and approvals

## II. Implement Purchasing Controls

- Ensure purchasing controls are adequate for all products/processes
- Define specifications that are clear and understood
- Document evaluation of suppliers
- Obtain agreement, where possible, to address changes to product or services

## III. Implement Effective CAPA Subsystem

- Document all CAPA SOPs
- Train staff on all applicable CAPA procedures
- Document and complete actions implemented according to CAPA SOPs
- Verify/validate CAPAs before closure
- Ensure management is aware of how the subsystem is performing

## III. Implement Effective CAPA Subsystem (cont)

- Continue to manage/improve the CAPA subsystem
- Identify linkages to other Quality System elements
- Establish and maintain complaint files
- Document and address all complaints per SOP
- Use proper tools for performing investigations

# **General Tips for Preventing FDA Regulatory Actions**

- Review and understand regulatory requirements
- Establish and maintain SOPs for all required activities
- Train employees on all applicable procedures
- Document all completed activities
- Ensure management is aware of how effective the quality system is performing

# Summary

- FDA regulatory actions correct violations and remove violative devices from the market.
- FDA can criminally prosecute responsible individuals who fail to address product and patient safety problems.
- Understanding your own operations and regulatory requirements helps prevent regulatory actions.
- Respond to regulatory action in a timely manner.



# Questions

Please complete the session survey:  
[surveymonkey.com/r/DEV-D2S07](https://surveymonkey.com/r/DEV-D2S07)

# Call to Action

- Understand and comply with all applicable FDA laws and regulatory requirements.
- Always respond to FDA regulatory actions within the appropriate time frame.

